Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: The spanish multicenter dihana study

J. R. Valdizán-Usón, A. Cánovas-Martínez, M. T. de Lucas-Taracena, F. Díaz-Atienza, L. S. Eddy-Ives, A. Fernández-Jaén, M. Fernández-Pérez, M. García-Giral, P. García-Magán, M. Garraus-Oneca, M. A. Idiazábal-Alecha, M. López-Benito, G. Lorenzo-Sanz, J. Martínez-Antón, M. A. Martínez-Granero, F. Montañés-Rada, F. Mulas-Delgado, G. Ochando-Perales, E. Ortega-García, A. Pelaz-AntolínJ. A. Ramos-Quiroga, F. C. Ruiz-Sanz, J. Vaquerizo-Madrid, A. Yusta-Izquierdo

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Background: The purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics. Methods: This multicenter, observational, retrospective, noninterventional study included 730 patients aged 4-65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002-2006 in sequential order. Results: The ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as "very satisfied" or "satisfied" by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy. Conclusion: Good efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD. © 2013 Valdiza ́n-Usón et al, publisher and licensee Dove Medical Press Ltd.
Original languageEnglish
Pages (from-to)211-218
JournalNeuropsychiatric Disease and Treatment
Volume9
DOIs
Publication statusPublished - 7 Feb 2013

Keywords

  • Adhd
  • Attention deficit hyperactivity disorder
  • Methylphenidate
  • Pharmacologic treatment
  • Satisfaction

Fingerprint Dive into the research topics of 'Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: The spanish multicenter dihana study'. Together they form a unique fingerprint.

Cite this